The Oncomine database indicated that CKAP2L is highly expressed in bladder cancer, brain and central nervous system cancer, breast cancer, cervical cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, and ovarian cancer (Figure 1B). This evidence concerns the gene CKAP2L and liver cancer.